Oncology & Cancer

Neoadjuvant chemotherapy key to survival in pancreatic cancer

(HealthDay)—Three factors can predict survival in patients with borderline resectable (BR) or locally advanced (LA) pancreatic ductal adenocarcinoma (PDAC), according to a study published online April 2 in the Annals of ...

Oncology & Cancer

Mechanisms ID'd for curcumin resensitization of cancer cells

(HealthDay)—Curcumin can resensitize chemoresistant pancreatic ductal adenocarcinoma (PDAC) cells through inhibition of the polycomb repressive complex 2 (PRC2)-PVT1-c-Myc axis, according to a study published online July ...

Oncology & Cancer

Overcoming resistance in pancreatic cancer

Cancer is relentless and resilient. When a drug blocks a cancer cell's main survival pathway, the cell avoids the obstacle by taking different pathways or detours to save itself. This tactic is called "developing resistance," ...

Medical research

Exploring a novel treatment for K-Ras mutant pancreatic tumors

Often undetected until it has progressed to an advanced stage, pancreatic ductal adenocarcinoma (PDAC) is a lethal cancer. The K-Ras mutant pancreatic cancer is one of the most common types. At present, there are no effective ...

page 6 from 11